Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Nasopharyngeal Carcinoma

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University20 enrolled

Overview

This phase II trial is studying cisplatin or nedaplatin combine with IMRT to evaluate which one is better efficacy and security in nasopharyngeal carcinoma.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Nasopharyngeal Carcinoma

Interventions

CisplatinDRUG

40mg/m2/w

NedaplatinDRUG

40mg/m2/w

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: Age≥18,T1-2aN1-3;T2-4NxNPC,VEGFR+,++,KPS\>70,Life expectancy≥6 months, No uncontrolled hypertension,cardiac failure,diabetes,lunacy Exclusion Criteria: Distant metastasis, recurrent disease

Locations (1)

Daping Hospital

Chongqing, China

Outcomes

Primary Outcomes

locoregionally control rate

3 months after treatment

Time frame: 3 months

Secondary Outcomes

Survival

1 year Progress Free Survival,Disease Free Survival,3 years and 5 years Over All Survival,Safety

Time frame: 1,3,5 years

Central Contacts

Zhenzhou Yang, Dr.

CONTACT

86(23)68757182 yangzhenzhou@sohu.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.